Comparative Pharmacology
Head-to-head clinical analysis: PROMETHAZINE DM versus ZUPLENZ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PROMETHAZINE DM versus ZUPLENZ.
PROMETHAZINE DM vs ZUPLENZ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, antiemetic via blockade of dopamine D2 receptors in the chemoreceptor trigger zone, and sedative via central anticholinergic effects. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist, suppressing cough by central action on the cough center.
Competitive serotonin 5-HT3 receptor antagonist; acts centrally on the chemoreceptor trigger zone and peripherally on GI vagal nerve terminals to inhibit emesis.
2 teaspoonfuls (10 mL) orally every 4-6 hours, not to exceed 8 teaspoonfuls (40 mL) per 24 hours.
8 mg administered intraorally as a single dose 1 hour before chemotherapy; may repeat once if vomiting occurs within 30 minutes after initial dose.
None Documented
None Documented
16-19 hours (terminal); note: effect may last longer due to active metabolites and tissue binding
Terminal elimination half-life 3.5 hours; in hepatic impairment increases to 7-9 hours
Renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Renal 70% unchanged, fecal 20% (including biliary metabolites), 10% metabolized
Category A/B
Category C
Antihistamine / Antiemetic
Antiemetic